IDEXX Laboratories (NASDAQ:IDXX) EVP Nimrata Hunt Sells 1,758 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Nimrata Hunt also recently made the following trade(s):

• On Thursday, February 26th, Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22.

IDEXX Laboratories Stock Performance

IDXX traded down $7.92 during midday trading on Friday, reaching $611.00. The company had a trading volume of 118,092 shares, compared to its average volume of 507,435. The business has a 50-day moving average price of $668.54 and a two-hundred day moving average price of $668.40. The stock has a market cap of $48.65 billion, a PE ratio of 46.75, a P/E/G ratio of 3.94 and a beta of 1.66. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $26,000. Reflection Asset Management acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $53,000. BDFS Capital LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $671,000. MidFirst Bank purchased a new stake in IDEXX Laboratories during the fourth quarter worth $2,960,000. Finally, Pacer Advisors Inc. increased its holdings in IDEXX Laboratories by 10.0% during the 4th quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock valued at $9,448,000 after acquiring an additional 1,269 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Barclays lowered their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.